Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC
GlobeNewswire•March 13, 2018
MINNEAPOLIS, March 13, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with SyntArray LLC. This license agreement will advance the Company’s strategic plan to develop the next generation of patient derived (“PDx”) tumor models for precision cancer therapy and drug development by granting it access to SyntArray’s targeted peptide cell capture technology.
TumorGenesis is developing a new approach to growing tumor models in the laboratory that is faster, less costly and more closely mimics the characteristics of the patient’s tumor, than the traditional PDx animal models that are currently on the market. TumorGenesis’ innovative approach is comprised of three key steps: first, the tumor cells from the patient tumor biopsy are tagged using peptides targeted to the patient’s specific cancer cells; second, the tags adhere the cells to a 3D biomimetic support in the well of a standard 96 well microplate; and third, the tumor cells are grown in the 3D culture system until ready for testing.
The SyntArray technology provides a vital step in rapidly identifying the key peptide ligands that cause the cells to attach to the surface of a microplate and grow. The SyntArray technology ensures that TumorGenesis is able to capture and grow all the different types of cancer cells in the laboratory to closely mimic the tumor inside the patient’s body for more relevant drug response testing.
Dr. Carl Schwartz, Chief Executive Officer of Precision Therapeutics, commented, “We are executing on our strategy to participate in the growth of the rapidly emerging precision medicine market by positioning the Company as an invaluable partner to Pharma companies as they develop personalized approaches to diagnosing and treating cancers. Securing this agreement to license the SyntArray technology is expected to further our plans to develop the next generation of patient derived tumor models. These patient-derived tumor models will be designed to ‘fool’ the cancer cells into thinking they are still in the patient’s body. Offering an external, structured environment that more closely mimics the characteristics of the patient’s tumor is expected to generate a more effective response when testing drugs for personalized therapy and in the development of new drugs, compared with the costlier, and less effective, animal models that are currently used in the clinical development of cancer therapies.”
Testing of patient tumors using the TumorGenesis approach is expected to:
a) Provide a personalized therapy protocol for a patient,
b) Provide high-quality data on cancer tumors for a platform based on the D-CHIP Artificial Intelligence (AI) platform of Helomics Corporation, pursuant to Precision Therapeutics’ partnership with Helomics, and
c) Drive partnerships with Pharma companies for the development of new therapies, generating revenues for Precision Therapeutics.
Testing of the TumorGenesis PDx tumors will take place in collaboration with Helomics. The Company is also currently in negotiations with several other medical technology companies to license their technologies and expects to announce these potential agreements when they are finalized.
About Precision Therapeutics Inc.
Precision Therapeutics (AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal.
Precision Therapeutics' CRO services business is committed to improving the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to rich data diseases databases. This business has launched with Precision Therapeutics' investment in Helomics Corporation, a precision diagnostic company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. In addition to its proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage our patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client's specific needs. Helomics is 25% owned by Precision Therapeutics. Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information, please visit www.Helomics.com. Precision Therapeutics has also announced the formation of a subsidiary, TumorGenesis to pursue a new rapid approach to growing tumors in the laboratory, which essentially “fools” the cancer cells into thinking they are still growing inside the patient. Precision Therapeutics and Helomics have also announced a proposed joint venture with GLG Pharma focused on using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering acquisitions in the precision medicine space.
Sold through the Skyline Medical business of Precision Therapeutics, The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S. For additional information, please visit www.skylinemedical.com.
